Phase III study did not show superiority of eribulin mesylate compared with capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes

A phase III open-label, randomized, multicentre study of eribulin mesylate in women with previously treated metastatic breast cancer failed to meet its co-primary endpoints of improved progression-free survival and overall survival compared with capecitabine, according to data presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium, held 4-8 December. Read more here.